• Something wrong with this record ?

Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy

F. König, SF. Shariat, PI. Karakiewicz, DH. Mun, M. Rink, B. Pradere

. 2021 ; 31 (4) : 291-296. [pub] 20210701

Language English Country United States

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21018414

PURPOSE OF REVIEW: The purpose of this article was to identify quality indicators for an optimized management of high-risk upper tract urothelial carcinoma (UTUC) requiring radical nephroureterectomy (RNU). RECENT FINDINGS: RNU with bladder cuff resection is the standard treatment of high-risk UTUC. For the bladder cuff resection, two main approaches are accepted: transvesical and extravesical. Lymph node dissection following a dedicated template should be performed in all high-risk patients undergoing RNU as it improves tumour staging and possibly survival. Postoperative bladder instillation of single-dose chemotherapy should be administered after RNU to decrease the risk of intravesical tumour recurrence. Perioperative systemic chemotherapy should always be considered for advanced cancers. Although level-1 evidence is available for adjuvant platinum-based chemotherapy, neoadjuvant regimens are still being evaluated. SUMMARY: Optimal management of high-risk UTUC requires evidence-based reproducible quality indicators in order to allow guidance and frameworks for clinical practices. Adherence to quality indicators allows for the measurement and comparison of outcomes that are likely to improve prognosis. Based on the literature, we found four evidence-based accepted quality indicators that are easily implementable to improve the management of high-risk UTUC patients treated with RNU: adequate management of the distal ureter/ bladder cuff, template-based lymph node dissection, single-shot postoperative intravesical chemotherapy, and perioperative systemic treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018414
003      
CZ-PrNML
005      
20210830100012.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000000895 $2 doi
035    __
$a (PubMed)33973537
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a König, Frederik $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
245    10
$a Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy / $c F. König, SF. Shariat, PI. Karakiewicz, DH. Mun, M. Rink, B. Pradere
520    9_
$a PURPOSE OF REVIEW: The purpose of this article was to identify quality indicators for an optimized management of high-risk upper tract urothelial carcinoma (UTUC) requiring radical nephroureterectomy (RNU). RECENT FINDINGS: RNU with bladder cuff resection is the standard treatment of high-risk UTUC. For the bladder cuff resection, two main approaches are accepted: transvesical and extravesical. Lymph node dissection following a dedicated template should be performed in all high-risk patients undergoing RNU as it improves tumour staging and possibly survival. Postoperative bladder instillation of single-dose chemotherapy should be administered after RNU to decrease the risk of intravesical tumour recurrence. Perioperative systemic chemotherapy should always be considered for advanced cancers. Although level-1 evidence is available for adjuvant platinum-based chemotherapy, neoadjuvant regimens are still being evaluated. SUMMARY: Optimal management of high-risk UTUC requires evidence-based reproducible quality indicators in order to allow guidance and frameworks for clinical practices. Adherence to quality indicators allows for the measurement and comparison of outcomes that are likely to improve prognosis. Based on the literature, we found four evidence-based accepted quality indicators that are easily implementable to improve the management of high-risk UTUC patients treated with RNU: adequate management of the distal ureter/ bladder cuff, template-based lymph node dissection, single-shot postoperative intravesical chemotherapy, and perioperative systemic treatment.
650    12
$a karcinom z přechodných buněk $x chirurgie $7 D002295
650    _2
$a lidé $7 D006801
650    12
$a nádory ledvin $x chirurgie $7 D007680
650    _2
$a lokální recidiva nádoru $x epidemiologie $7 D009364
650    _2
$a nefroureterektomie $7 D000074682
650    _2
$a ukazatele kvality zdravotní péče $7 D019984
650    _2
$a retrospektivní studie $7 D012189
650    12
$a ureter $x chirurgie $7 D014513
650    12
$a nádory močovodu $x chirurgie $7 D014516
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, New York $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
700    1_
$a Mun, Dong-Ho $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Rink, Michael $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 31, č. 4 (2021), s. 291-296
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33973537 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100013 $b ABA008
999    __
$a ok $b bmc $g 1689507 $s 1138858
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 31 $c 4 $d 291-296 $e 20210701 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options